Sai Life Sciences Limited has announced the completion of Phase II of its new Production Block 11 (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka. With this expansion, the company’s total installed reactor capacity at the site now stands at approximately 700 KL.
Phase I of PB-11, with a capacity of 110 KL, was inaugurated in December 2024. The newly completed Phase II adds another 91 KL, making PB-11 the single largest reactor volume block at the Bidar unit with a combined capacity of ~200 KL.
Commenting on the development, Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, said the expansion goes beyond additional capacity, aiming to provide clients with confidence in scalability, reliability, and the ability to handle increasingly complex projects.
The Bidar facility now comprises 12 production blocks and is equipped with specialized capabilities such as high-potency API manufacturing, lyophilization, cryogenic and high-pressure reactions, and commercial-scale chromatography. It has been successfully inspected and approved by leading global regulatory agencies, including the USFDA, PMDA (Japan), and CDSCO (India).
As of March 2025, Sai Life Sciences’ manufacturing units had undergone over 75 customer audits in three years, reflecting its commitment to quality and compliance.
